Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis

Molecular Diagnosis and Therapy

Volumn 15, Issue 1, 2011, Pages 21-29

  Hlinkova, Katarina ^a   Babl, Pavel ^b   Berzinec, Peter ^c   Majer, Ivan ^b   Ilencikova, Denisa ^d  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^d University Children's Hospital Bratislava   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOLOGY; EXON; FRAMESHIFT MUTATION; GENE DELETION; GENE MUTATION; GENETIC PROCEDURES; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TITRIMETRY; TUMOR CELL;

BASE SEQUENCE; CELL LINE, TUMOR; GENES, ERBB-1; HUMANS; MUTATION; NEOPLASMS; NUCLEIC ACID DENATURATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

EID: 79953779287     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11586950-000000000-00000     Document Type: Article

References (33)

1. National Health Information Center. Health statistics yearbook of the Slovak Republic 2008. Bratislava: National Health Information Center, 2009: 208
2. Uddin D. Non-small cell lung cancer (NSCLC): an update. TAJ: Journal of Teachers Association 2002; 15: 115-8 [online]. Available from URL: http://www.banglajol.info/index.php/TAJ/article/view/3923 [Accessed 2011 Mar 1]
3. Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin 2007; 57: 43-66
4. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFRTKI treatment for patients with lung cancer? Br J Cancer 2007; 96: 857-63
5. Katzel JA, Fanutcchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol 2009; 2: 1-18
6. Gazdar AF, Minna JD. Deregulated EGFR signaling during lung cancer progression: mutations, amplicons and autocrine loops. Cancer Prev Res 2008; 1: 156-60
7. Nair P. Epidermal growth factor receptor family and its role in cancer progression. Current Science 2005; 88: 890-8 (Pubitemid 40793573)
8. Neal JW, Sequist V. Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nat Rev Clin Oncol 2010; 7: 71-2
9. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation and clinical response to gefitinib therapy. Science 2004; 304: 1497-500 (Pubitemid 38720929)
10. Yun CH, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11: 217-27 (Pubitemid 46349842)
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor underlying responsiveness of NSCLC to gefitinib. N Engl J Med 2004; 350: 2129-39 (Pubitemid 38637993)
12. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11 (Pubitemid 39209661)
13. Reed GH, Kent JO, Wittwer CT. High resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 2007; 8: 597-608 (Pubitemid 46939585)
14. Wittwer CT, Reed GH, Gundry CN, et al. High resolution genotyping by amplicon melting analysis using LC Green. Clin Chem 2003; 49: 853-60 (Pubitemid 36623462)
15. Kimura H, Fijiwara Y, Sone T, et al. High sensitivity detection of EGFR mutations in the pleural effusion of NSCLC patients. Cancer Sci 2006; 97: 642-8
16. Cohen V, Aqulnik JS, Jarry J, et al. Evaluation of denaturating high-performance liquid chromatography as a rapid detection method for identification of EGFR mutations in NSCLC. Cancer 2006; 107: 2858-65 (Pubitemid 44937040)
17. Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched PCR polymerase chain reaction assay. Clin Cancer Res 2006; 12: 43-8 (Pubitemid 43166174)
18. Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archieved cytologic specimens ofNSCLC usingHRMA.AmJClin Pathol 2006; 126: 608-15
19. Fukui T, Ohe Y, Tsuta K, et al. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 2008; 14: 4751-7
20. Heideman DAM, Thunnisen FB, Doeleman M, et al. A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cellular Oncology 2009; 31: 329-33
21. Fassina A, Gazziero A, Zardo D, et al. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. J Clin Pathol 2009; 62: 1096-102
22. Takano T, Ohe Y, Fukui T, et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non-small cell lung cancer treated with gefitinib. Clin Cancer Res 2007; 13: 5385-90 (Pubitemid 47510364)
23. Chin TM, AnuarD, Soo R, et al. Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem 2007; 53: 62-70 (Pubitemid 46047764)
24. Janne PA, Borras AM, KuangY, et al.Arapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006; 12: 751-8 (Pubitemid 43259854)
25. Takano T, Ohe T, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 6829-37
26. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23: 857-65 (Pubitemid 46224186)
27. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor genemutations in lung adenocarcinomas. J Mol Diagn 2005; 7: 396-403 (Pubitemid 41149655)
28. MiyazawaH, Tanaka T,Nagai Y, et al. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Science 2008; 99: 595-600 (Pubitemid 351228579)
29. Endo K, Konishi A, Sasaki H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 2005; 50: 375-84
30. Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006; 12: 3915-21 (Pubitemid 44078075)
31. Do H, Krypuy M, Mitchell PL, et al. High resolutionmelting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008; 8: 1-14
32. Do H, Dobrovic A. Limited copy number-high resolution melting (LCNHRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer 2009; 8: 1-11
33. Quach N, Goodman F, Shibata D. In vitro mutation artifacts after formalin fixation and error prone translesion synthesis during PCR. BMC Clin Pathol 2004; 4: 1